1
|
Loughran EA, Leonard AK, Hilliard TS, Phan RC, Yemc MG, Harper E, Sheedy E, Klymenko Y, Asem M, Liu Y, Yang J, Johnson J, Tarwater L, Shi Z, Leevy M, Ravosa MJ, Stack MS. Aging Increases Susceptibility to Ovarian Cancer Metastasis in Murine Allograft Models and Alters Immune Composition of Peritoneal Adipose Tissue. Neoplasia 2018; 20:621-631. [PMID: 29754071 PMCID: PMC5994778 DOI: 10.1016/j.neo.2018.03.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 03/20/2018] [Accepted: 03/26/2018] [Indexed: 11/30/2022] Open
Abstract
Ovarian cancer, the most deadly gynecological malignancy in U.S. women, metastasizes uniquely, spreading through the peritoneal cavity and often generating widespread metastatic sites before diagnosis. The vast majority of ovarian cancer cases occur in women over 40 and the median age at diagnosis is 63. Additionally, elderly women receive poorer prognoses when diagnosed with ovarian cancer. Despite age being a significant risk factor for the development of this cancer, there are little published data which address the impact of aging on ovarian cancer metastasis. Here we report that the aged host is more susceptible to metastatic success using two murine syngeneic allograft models of ovarian cancer metastasis. This age-related increase in metastatic tumor burden corresponds with an increase in tumor infiltrating lymphocytes (TILs) in tumor-bearing mice and alteration of B cell-related pathways in gonadal adipose tissue. Based on this work, further studies elucidating the status of B cell TILs in mouse models of metastasis and human tumors in the context of aging are warranted.
Collapse
Affiliation(s)
- Elizabeth A Loughran
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN; Integrated Biomedical Sciences Graduate Program, University of Notre Dame, Notre Dame, IN; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Annemarie K Leonard
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Tyvette S Hilliard
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Ryan C Phan
- Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Madeleine G Yemc
- Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Elizabeth Harper
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Emma Sheedy
- Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Yuliya Klymenko
- Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN; Department of Biological Sciences, University of Notre Dame, Notre Dame, IN
| | - Marwa Asem
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN; Integrated Biomedical Sciences Graduate Program, University of Notre Dame, Notre Dame, IN; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Yueying Liu
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Jing Yang
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Jeff Johnson
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Laura Tarwater
- Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Zonggao Shi
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN
| | - Matthew Leevy
- Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN; Department of Biological Sciences, University of Notre Dame, Notre Dame, IN
| | - Matthew J Ravosa
- Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN; Department of Biological Sciences, University of Notre Dame, Notre Dame, IN; Department of Aerospace and Mechanical Engineering, University of Notre Dame, Notre Dame, IN; Department of Anthropology, University of Notre Dame, Notre Dame, IN
| | - M Sharon Stack
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN; Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN.
| |
Collapse
|
2
|
Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol 2016; 78:745-52. [PMID: 27522647 DOI: 10.1007/s00280-016-3100-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Accepted: 07/06/2016] [Indexed: 01/21/2023]
Abstract
PURPOSE Weekly dose-dense paclitaxel (PTX) in combination with carboplatin (CBDCA) every 3 weeks (ddTC therapy) is a standard treatment for patients with advanced ovarian cancer. However, there is no detailed analysis of the feasibility of ddTC therapy in elderly patients with ovarian cancer. METHODS We identified patients diagnosed with ovarian, fallopian tube, or peritoneal cancer who received ddTC therapy at the National Cancer Center Hospital from April 2003 to April 2013. We assessed the feasibility of ddTC therapy in elderly patients aged 70 years or older (elderly group), comparing relative dose intensity (RDI) for PTX, CBDCA, and ddTC; adverse events; and rate of chemotherapy discontinuation to those in patients below 70 years of age (younger group). RESULTS A total of 143 patients (elderly group, 22; younger group, 121) was analyzed. A comparison of RDI between these two groups showed no significant differences for PTX, CBDCA, and ddTC. Nonhematological and hematological toxicity profiles of the elderly and younger groups were similar, except that severe peripheral neuropathy (Grade 2 or higher) was more common in the elderly group. There was no significant difference in the rate of chemotherapy discontinuation (elderly group, 13.6 % vs. younger group, 7.4 %, p = 0.397). CONCLUSIONS Our study showed that ddTC therapy was feasible for elderly patients. However, to prevent severe neuropathy, PTX dose reduction deserves consideration.
Collapse
|
3
|
Tew WP. Ovarian cancer in the older woman. J Geriatr Oncol 2016; 7:354-61. [PMID: 27499341 DOI: 10.1016/j.jgo.2016.07.008] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Revised: 05/02/2016] [Accepted: 07/18/2016] [Indexed: 02/08/2023]
Abstract
Ovarian cancer is the seventh most common cancer in women worldwide and accounts for nearly 4% of all new cases of cancer in women. Almost half of all patients with ovarian cancer are over the age of 65 at diagnosis, and over 70% of deaths from ovarian cancer occur in this same age group. As the population ages, the number of older women with ovarian cancer is increasing. Compared to younger women, older women with ovarian cancer receive less surgery and chemotherapy, develop worse toxicity, and have poorer outcomes. They are also significantly under-represented in clinical trials and thus application of standard treatment regimens can be challenging. Performance status alone has been shown to be an inadequate tool to predict toxicity of older patients from chemotherapy. Use of formal geriatric assessment tools is a promising direction for stratifying older patients on trials. Elderly-specific trials, adjustments to the eligibility criteria, modified treatment regimens, and interventions to decrease morbidities in the vulnerable older population should be encouraged.
Collapse
|
5
|
Güth U, Arndt V, Stadlmann S, Huang DJ, Singer G. Epidemiology in ovarian carcinoma: Lessons from autopsy. Gynecol Oncol 2015; 138:417-20. [PMID: 26005053 DOI: 10.1016/j.ygyno.2015.05.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 05/13/2015] [Indexed: 11/24/2022]
Abstract
OBJECTIVE We challenge epidemiologic knowledge regarding ovarian carcinoma (OC) by bridging the gap between clinical and autopsy data. METHODS Autopsy reports, histological slides and clinical files from 660 patients in whom OC was diagnosed from 1975-2005 were studied (autopsy cohort, n=233; Clinical Cancer Registry from the local gyneco-oncologic center, n=427). RESULTS Out of the autopsy cohort, we identified four distinct subgroups of patients: 1) OC was diagnosed before autopsy, n=156 (67.0%). 2) OC was an incidental finding, n=16 (6.8%). 3) The ovarian tumors were not primary OC but rather metastases from other primary tumors; this revised diagnosis was first made by using current histopathological knowledge/techniques, n=24 (10.3%). 4) Death was directly due to OC in its final stage and OC was first diagnosed by autopsy, n=37 (15.9%); when these cases were added to the Clinical Cancer Registry to an adjusted OC incidence model, the autopsy cases comprised 8.8% of the adjusted cohort and almost doubled the percentage of oldest patients (≥80 years at diagnosis) from 4.9% to 9.3% (p=0.013). CONCLUSIONS Epidemiological data from the 1970s-1990s may overestimate true incidence because up to 10% of carcinomas in the ovary were not properly classified. Patients who were first diagnosed with OC by autopsy comprise a distinct subgroup. These are patients who have not been seen by specialized oncologists and thus play no role in their perception of the disease. Nevertheless, these cases have impact on prevalence and incidence data of OC and in an era of reduced autopsy rates will probably be overlooked.
Collapse
Affiliation(s)
- Uwe Güth
- Cantonal Hospital Winterthur, Department of Gynecology & Obstetrics, Brauerstrasse 45, CH-8401 Winterthur, Switzerland; University Hospital Basel (UHB), Department of Gynecology and Obstetrics, Spitalstrasse 21, CH-4031 Basel, Switzerland.
| | - Volker Arndt
- National Institute for Cancer Epidemiology and Registration (NICER), c/o University of Zurich, Epidemiology, Biostatistics and Prevention Institute. Seilergraben 49, CH-8001 Zürich, Switzerland
| | - Sylvia Stadlmann
- Kantonsspital Baden AG, Institute of Pathology, CH-5404 Baden, Switzerland; University Hospital Basel of Basel, Institute of Pathology, Schönbeinstrasse 40, CH-4031 Basel, Switzerland
| | - Dorothy Jane Huang
- University Hospital Basel (UHB), Department of Gynecology and Obstetrics, Spitalstrasse 21, CH-4031 Basel, Switzerland
| | - Gad Singer
- Kantonsspital Baden AG, Institute of Pathology, CH-5404 Baden, Switzerland; University Hospital Basel of Basel, Institute of Pathology, Schönbeinstrasse 40, CH-4031 Basel, Switzerland
| |
Collapse
|
8
|
CA125 level association with chemotherapy toxicity and functional status in older women with ovarian cancer. Int J Gynecol Cancer 2014; 23:1022-8. [PMID: 23765208 DOI: 10.1097/igc.0b013e318299438a] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
OBJECTIVE Older women with ovarian cancer have increased cancer-related mortality and chemotherapy toxicity. CA125 is a sensitive biomarker for tumor burden. The study evaluates the association between CA125, geriatric assessment (GA), and treatment toxicity. METHODS This is a secondary subset analysis of patients 65 years or older with ovarian cancer accrued to a multicenter prospective study that developed a predictive toxicity score for older adults with cancer. Clinical and geriatric covariates included sociodemographics, GA (comorbidity, social support, functional, nutritional, psychological, cognitive status), treatment, and laboratory studies. Using bivariate analyses, we determined the association of abnormal CA125 (≥35 U/mL) with baseline GA, grades 3 to 5 toxicity (Common Terminology Criteria for Adverse Events version 3), dose adjustments, and hospitalization. Logistic regression analysis was used to check for potential confounder for association between CA125 and chemotherapy toxicity. RESULTS Fifty-one (10%) of 500 patients accrued to the primary study had a diagnosis of ovarian (92%), peritoneal (4%), or fallopian tube (4%) cancer. Median age was 72 years (range, 65-86 years). Forty-six patients (90%) had stage III-IV disease. Twenty-three patients (45%) received first-line chemotherapy, and 34 (67%) received platinum-doublet therapy. Thirty-six (71%) had an abnormal CA125. Grades 3 to 5 toxicity occurred in 19 patients (37%). Abnormal CA125 was associated with assistance with instrumental activities of daily living (P < 0.05), lower performance status (P = 0.05), grades 3 to 5 toxicity (P = 0.03), nonheme toxicity (P = 0.04), and dose reductions (P = 0.01). No association between CA125 level and total toxicity score was observed. CONCLUSIONS Among older women with ovarian cancer, abnormal CA125 was associated with poor pretreatment functional status and an increased probability of chemotherapy toxicity and dose reduction.
Collapse
|
9
|
Teo MY, Power DG, Tew WP, Lichtman SM. Doublet chemotherapy in the elderly patient with ovarian cancer. Oncologist 2012; 17:1450-60. [PMID: 22915061 PMCID: PMC3500367 DOI: 10.1634/theoncologist.2012-0155] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2012] [Accepted: 07/25/2012] [Indexed: 11/17/2022] Open
Abstract
The aging of the population has focused on the need to evaluate older patients with cancer. Approximately 50% of patients with ovarian cancer will be older than age 65 years. Increasing age has been associated with decreased survival. It is uncertain whether this relates to biologic factors, treatment factors, or both. There is concern that undertreatment may be associated with decreased survival. Older patients with ovarian cancer have been underrepresented in clinical trials. Therefore, the evidence base on which make decisions is lacking. Clinicians need to be aware of the currently available data to aid in treatment decisions. Doublet therapy is the most common standard treatment in epithelial ovarian cancer. It usually consists of a taxane and a platinum compound. A series of cooperative group studies in both the United States and Europe established intravenous paclitaxel and carboplatin as the most common standard in optimally debulked patients. The recent introduction of intraperitoneal therapy has complicated decision making in terms of which older patients would benefit from this more toxic therapy. In relapsed patients, the issue of platinum sensitivity is critical in deciding whether to reutilize platinum compounds. It is unclear whether single agents or combinations are superior, particularly in older patients. Geriatric assessment is an important component of decision making. Prospective studies are needed to develop strategies to determine the optimal treatment for older patients with ovarian cancer.
Collapse
Affiliation(s)
- Min Y. Teo
- Department of Medical Oncology, Cork/Mercy University Hospitals, Cork, Ireland
| | - Derek G. Power
- Department of Medical Oncology, Cork/Mercy University Hospitals, Cork, Ireland
| | | | - Stuart M. Lichtman
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
| |
Collapse
|